2. WHO ARE WE
Established
in
1994
as
a
Medical
Technology
Developer
and
Patent
Holding
Company
(Formerly
Known
as
LaMina
Inc.)
Inventor
of
the
First
Test
in
the
Cup
(Genie
Cup)
for
Drugs
of
Abuse
tesJng,
First
Monolayer
Liquid
PreparaJon
(MonoPrep)
Cytology
to
replace
PAP-‐Smear
for
Cervical
Cancer
Screening
And
First
Saliva
Based
Colloidal
Gold
(Nanotechnology)
Point
of
Care
and
PaJent
ID
Test.
3. BTP(Background)
BTP’s Technology Platform
• BioTechPharma, LLC ("BTP") has developed and patented a
front-end collection and testing platform. e product
platform is a ‘One-Step” collection and rapid On-Site testing
nanotechnology-based microfluidic device. e device has a
built-in feature to capture test subject's fingerprints while
collecting his/her DNA for sample identification.
• Essentially, BioTechPharma's platform can be used to test
virtually any metabolite, protein, or biomarker found in a
human as well as most other environmental or biological
samples.
• BTP's business model is to manufacture, sell, and license its
products to the "Point of Care", test screening,
environmental and biometric markets. BTP's platform has
many applications including but not limited to drug of
abuse, infectious diseases, cancer detection, environmental,
and bio-defense.
• e business strategy of the company is to establish strategic
partnerships with companies and organizations to exploit the
platform for profitable applications.
http://www.youtube.com/watch?v=giyf0cslVow
4. Our Vision
To
Make
Healthcare
Affordable
To
All
NaJons
Around
the
Globe
And
To
Enable
People
To
be
more
proacJve
about
their
health
to
Do
More
for
Less.
This
Can
Be
Achieved
Through
InnovaJve
Offerings
And
Unique
Value
ProposiJons
Across
the
Full
Spectrum
of
Healthcare
including
Manufacturing
of
Consumer
Health
Products
and
PaJent
Monitoring
Devices.
5. Our Mission
To
Provide
an
Affordable
InnovaJve
SoluJons
via
AlternaJve
Offerings
to
the
Healthcare
Community
to
enhance
the
Quality
of
Services
For
Caregivers
while
enhancing
Consumer
Values.
To
Introduce
New
Trends
in
Healthcare
Consumer
Privacy
&
InformaJon
Security
while
CreaJng
New
OpportuniJes
for
Employments
in
the
rapidly
growing
Healthcare
Economy
6. Core Values
Commitment
To
Excellence
via
InnovaJon,
Integrity,
and
Social
Responsibility.
Job
creaJon
to
Enable
Each
In-‐Country
Partnership
to
parJcipate
in
the
New
Global
Healthcare
economy
7. KSA (Introduction)
In-Country HealthCare Partnership
Healthcare Spending as a
(%) of GDP for
• Healthcare
environment
• 12B+ healthcare spending in capital equipment and related supplies and services,
Average annual growth between 5% - 10%
• Major Cause of Death: Cardiovascular, Cancer, and Diabetes
• MOH Total Budget of SR 22B in 2007
• SR 2000M FMS addressable Market
• 383 hospitals / > 55K beds
324 MOH hosp. / 35,000 beds
27 military / 4,755 beds
5 National Guard / 1,530 beds
5 Teaching Hospitals / 1,770 beds
ARAMCO / 560 beds
2 Royal Commission / 949 beds
15 > 200 beds ( Private) / 9,735 beds
3 Security Forces Hosp. / 570 beds
1 KFSH / 500 beds
15
10.9
9.7
8.5
4.3
3.8
4.1
2.7
4.1
USA Ger Fra Italy KSA Kuwait UAE Qatar Bahrain
8. Estimated KSA Market Size
Capital Equipment & Related Consumables and
Services
MOH
MODA
NGHA
KFSH
Teach
Private
Others
HIT
Services
Non-‐Medical
Consumables
Total
Market
Size
SR
39,860,200
Capital
Equipment
+
9. Future Market Drivers
• Worldwide:
• Most hospitals, clinics, trauma centers, physicians, and patients
will be connected to one large network enabling access to
critical medical information.
• The medical industry will face an ethical and social issues over
the disclosure of patient information that causes patient
Information privacy and security to become an integral part of
the healthcare systems.
• Advanced nanotechnology and genetic will eliminate many
diseases, accelerate healing, and increase longevity.
• Personalized Medicine will lead to new generation of smart
phone applications, drugs, implants, and medical devices that
will enhance our health and performance.
• Virtual-reality medical simulations will become the dominant
mode of medical training.
• Cyber-health care that is customized for us—designed to
monitor, diagnose, educate, and intervene regardless of
location or time—will be common.
KSA:
• Demand for Integrations of clinical IT solutions and
wireless healthcare communication devices will drive the
need for information security and patient privacy.
• Growing pressures for direct presence of suppliers and
made-in the KSA will continue to increase to create new
jobs in the Kingdom.
• Move to innovation to design and build outreach satellite
healthcare centers to provide quality healthcare to remote
site populations in the KSA.
• Increased acceptance for Over The Counter (OTC) and
“yellow” products in Saudi Public and Private Hospitals
and out-patient clinics
• Quality level of post-sales-support is increasingly more
important to customers than brand names will drive the
need for Healthcare Call-Centers and Web-Based
Information Sites.
• Saudi Food & Drugs Agency (S-FDA) – newly established
regulatory body Change of competitive landscape..
• Insurance coverage for early detection and pro-health
screening.
10. BTP Target Users
and Market Segments
• BTP Integrated Sample Collection and Testing
Devices are significantly different from other Over–
The-Counter (OTC) products. They have a built in
tamper proof lock plus a split sample vial for additional
laboratory testing.
Integrated Sample Collection & Testing Devices
11. BTP
Current Product Offerings
Saliva
• Saliva Based Kits for Drugs of Abuse Testing for use at VISA &
Immigration offices (Point-of-Entry/OTC) and Roadside
Testing of 12 Drugs including Alcohol (available Oct. 2013)
• Saliva Based Kits for Hormonal & Endocrine Measurements of
Diabetes and Nutritional Diseases (Available June 2014)
• Saliva Based Kits for DNA Analysis for use with Personalized
Medicine and Chromosomal Analysis of Genetic Diseases.
• Cervical & Endometrial Swabs for Detection of Cervical Cancer
using HPV Chromosomal Markers and Cervical Cytology.
(available Oct. 2014)
• Saliva Based erapeutic Drug Monitoring Kits
Urine &
Other Body Fluids
• Urine Based (OTC) Drugs of Abuse Kits for 23 different
Drugs and Alcohol (available Oct. 2013)
• Urinary Cardiac Markers for Early Detection of Coronary
Heart Diseases and Angina Pectoris. (available June 2014)
• Urinary Tumor Markers for Bladder Cancers & Kidney
Cancers. (Available June 2014)
• Hormonal & Endocrine Nutritional Urinary Markers for
Diabetes and Nutritional Diseases (Available June 2014)
• Occult Blood in the Stool Detection Kits for Early
Detection of Colon Cancers.
18. BTP
(Subsidiaries & Partners)
Is e Right Partner For Your Hospitals Group
To meet your Supply Chain & HealthCare Needs in the New Era of Internet Economy.
